BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts

Reuters

01-14

BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts

** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket

** Contract research firm sees its 2025 adj EPS between $13 and $15

** The midpoint is lower than Wall Street estimates of $14.83 - LSEG

** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln

** "Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses," CEO Steve Cutler says

** "Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters" - brokerage Evervore ISI

** Co reaffirms 2024 adj EPS and rev outlooks

** ICLR stock fell 25.9% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503575095"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503575095\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503575095?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503575095","market":"us","top_or_hot":-1,"title":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Icon falls on downbeat 2025 profit, revenue forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-14 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICLR","symbol_name":"ICON plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nL4N3OA14B:1","article_id":"2503575095","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503575095","pubTimestamp":1736863707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICLR":"ICON plc"},"translate_title":"BUZZ-Icon因2025年利润和收入预测悲观而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICLR":0.9},"content_text":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024 (Reporting by Puyaan Singh) ((Puyaan.Singh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}